文献速递心力衰竭与心肌病肺血管病与心包/心肌炎

甲基苯丙胺使用与戒断对甲基苯丙胺相关心力衰竭的临床与超声心动图结局

Clinical and echocardiographic outcomes in heart failure associated with methamphetamine use and cessation.
PubMed 文献 · Heart · 2020-10-05

本研究为回顾性队列研究,纳入甲基苯丙胺相关射血分数降低心衰(METHrEF)28例、射血分数保留心衰(METHpEF)28例及无甲基苯丙胺使用的心衰对照32例,随访超声指标至12个月、临床结局至24个月。METHrEF患者戒断后射血分数改善(+10.6±13.1%,p=0.009)且年心衰住院次数更少;METHpEF患者戒断后未见超声参数与临床结局的显著改善。

要点

  • METHrEF患者戒断甲基苯丙胺与左室收缩功能改善及心衰住院减少相关。
  • METHpEF患者基线右室收缩压高于对照,但戒断后未见显著超声或临床改善。
  • METHrEF可能具有可逆性,戒断应作为管理重点。

核心结论

  • METHrEF患者戒断甲基苯丙胺后左室收缩功能显著改善且心衰住院次数更少,提示METHrEF可能可逆。
  • METHpEF患者戒断后未观察到超声心动图参数与临床结局的显著改善。
  • METHpEF患者超声参数提示部分患者可能存在肺动脉高压而缺乏明显左室舒张功能障碍征象,但需进一步研究。

研究设计与样本

  • 回顾性队列研究,复习METHrEF、METHpEF及无甲基苯丙胺使用的心衰对照患者的病历。
  • 超声心动图变量记录至12个月,临床随访延长至24个月。
  • METHrEF组n=28,平均年龄51±9岁,男性82.1%;METHpEF组n=28,平均年龄50±8岁,男性60.7%;对照组n=32。

主要发现

  • METHrEF患者戒断与射血分数改善相关(+10.6±13.1%,p=0.009)。
  • METHrEF戒断者年心衰住院次数少于继续使用者(中位0.0,IQR 0.0-1.0 vs 中位2.0,IQR 1.0-3.0,p=0.039)。
  • METHpEF患者基线右室收缩压高于对照(中位53.44,IQR 43.70-84.00 vs 中位36.64,IQR 29.44-45.95,p=0.011)。
  • METHpEF患者侧壁E/E'比值低于对照(8.1±3.6 vs 11.2±4.,p<0.01)。

临床怎么用

  • 对METHrEF患者应强调甲基苯丙胺戒断,因其与左室收缩功能改善及心衰住院减少相关。
  • METHpEF患者需关注肺动脉高压可能,戒断后仍需继续评估与随访。

局限性

  • 本研究为回顾性队列研究,样本量较小(METHrEF n=28、METHpEF n=28、对照n=32)。
  • METHpEF患者特征及戒断后结局需额外研究进一步刻画。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Methamphetamine use is associated with systolic dysfunction, pulmonary arterial hypertension and may also be associated with diastolic dysfunction. The impact of methamphetamine cessation on methamphetamine-associated heart failure (MethHF) remains poorly characterised. We aimed to longitudinally characterise methamphetamine-associated heart failure patients with reduced (METHrEF) and preserved (METHpEF) left ventricular ejection fraction (EF), and evaluate the relationship between methamphetamine cessation and clinical outcomes. METHODS: We performed a retrospective cohort study, and reviewed medical records of patients with METHrEF, METHpEF and heart failure controls without methamphetamine use. Echocardiographic variables were recorded for up to 12 months, with clinical follow-up extending to 24 months. RESULTS: Among METHrEF patients (n=28, mean age 51±9 years, 82.1% male), cessation was associated with improvement in EF (+10.6±13.1%, p=0.009) and fewer heart failure admissions per year compared with continued use (median 0.0, IQR 0.0-1.0 vs median 2.0, IQR 1.0-3.0, p=0.039). METHpEF patients (n=28, mean age 50±8 years, 60.7% male) had higher baseline right ventricular systolic pressure (median 53.44, IQR 43.70-84.00 vs median 36.64, IQR 29.44-45.95, p=0.011), and lower lateral E/E' ratio (8.1±3.6 vs 11.2±4., p<0.01) compared with controls (n=32). Significant improvements in echocardiographic parameters and clinical outcomes were not observed following cessation in this group. CONCLUSIONS: METHrEF patients who cease methamphetamine use have significant improvement in left ventricular systolic function and fewer heart failure admissions, suggesting that METHrEF may be reversible. Echocardiographic parameters suggest that some patients with METHpEF may have pulmonary hypertension in the absence of overt signs of left ventricular diastolic dysfunction, but additional study is needed to characterise this patient cohort.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Bhatia HS, Nishimura M, Dickson S, et al. Clinical and echocardiographic outcomes in heart failure associated with methamphetamine use and cessation. Heart. 2020. PMID: 33020227. doi:10.1136/heartjnl-2020-317635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。